Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,083 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 41,083 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ASPENTECH Corp
Report date May 16, 2022 · Filed May 18, 2022
Section 16 reporting ended · disclosed 2022-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 1
1 source rowRow 1 · 2022-05-16 · Disposition to issuer · Disposed 3,465 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.97 · Expires 2029-04-16 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-16 · Disposition to issuer · Disposed 1,684 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F3: One third of the option granted at the exercise price of $109.97 will vest on the first anniversary of the grant date and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.20 · Expires 2029-09-02 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-16 · Disposition to issuer · Disposed 1,444 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F6: The option granted at the exercise price of $133.20 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.51 · Expires 2030-12-27 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-16 · Disposition to issuer · Disposed 303 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F7: The option granted at the exercise price of $130.51 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $129.50 · Expires 2031-08-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-16 · Disposition to issuer · Disposed 1,531 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F8: The option granted at the exercise price of $129.50 was fully vested on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech.
F3: One third of the option granted at the exercise price of $109.97 will vest on the first anniversary of the grant date and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested.
F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time.
F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent.
F6: The option granted at the exercise price of $133.20 was fully vested on the date of grant.
F7: The option granted at the exercise price of $130.51 was fully vested on the date of grant.
F8: The option granted at the exercise price of $129.50 was fully vested on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267500 · ownership.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001193125-26-266241 · ownership.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2036-06-08 F2 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266241 · ownership.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,083 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 12, 2025 Filed Jun 18, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-087881 · ownership.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 11, 2025 Filed Jun 18, 2025 20:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,450 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0000950170-25-087887 · ownership.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2025 Filed Jun 18, 2025 20:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087887 · ownership.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,883 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,515 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073702 · ownership.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2034-06-11 F2 · derivative.exercise_date: This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073702 · ownership.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,883 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:13 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-073013 · ownership.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 6,473 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037892 · doc4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 6,473 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037892 · doc4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,146 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-015008 · doc4.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F1 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000899243-22-038685 · doc4.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2032-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:40 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037602 · doc4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:40 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037602 · doc4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,721 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-035459 · doc4.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:45 UTC | ASPENTECH Corp AZPN · Entity 127212 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,531 | Not disclosed Strike: $129.50 | Not disclosed |
DisclosureSEC source: 0001127602-22-014973 · form4.xml · derivative · entry 5 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,531 shares Expires 2031-08-31 F1 · kind: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4 · price: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5 · price: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F8 · derivative.exercise_date: The option granted at the exercise price of $129.50 was fully vested on the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:45 UTC | ASPENTECH Corp AZPN · Entity 127212 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 303 | Not disclosed Strike: $130.51 | Not disclosed |
DisclosureSEC source: 0001127602-22-014973 · form4.xml · derivative · entry 4 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 303 shares Expires 2030-12-27 F1 · kind: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4 · price: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5 · price: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F7 · derivative.exercise_date: The option granted at the exercise price of $130.51 was fully vested on the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:45 UTC | ASPENTECH Corp AZPN · Entity 127212 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,444 | Not disclosed Strike: $133.20 | Not disclosed |
DisclosureSEC source: 0001127602-22-014973 · form4.xml · derivative · entry 3 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,444 shares Expires 2029-09-02 F1 · kind: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4 · price: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5 · price: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F6 · derivative.exercise_date: The option granted at the exercise price of $133.20 was fully vested on the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:45 UTC | ASPENTECH Corp AZPN · Entity 127212 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,684 | Not disclosed Strike: $109.97 | Not disclosed |
DisclosureSEC source: 0001127602-22-014973 · form4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,684 shares Expires 2029-04-16 F1 · kind: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4 · price: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5 · price: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F3 · derivative.exercise_date: One third of the option granted at the exercise price of $109.97 will vest on the first anniversary of the grant date and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:45 UTC | ASPENTECH Corp AZPN · Entity 127212 | Disposition to issuerCommon Stock | 3,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014973 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:59 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 826 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014476 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,465 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock Units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:27 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,531 | $129.50 Strike: $129.50 | $198,264.50 |
DisclosureSEC source: 0001127602-21-024890 · form4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,531 Underlying: Common Stock · 1,531 shares Expires 2031-08-31 F3 · derivative.exercise_date: The option granted at the exercise price of $129.50 was fully vested on the date of grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:27 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024890 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock Units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 3,382 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0001209191-21-043381 · doc4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043381 · doc4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 23, 2021 Filed Apr 15, 2022 00:44 UTC Amendment | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 2,534 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0000899243-22-014838 · doc4a.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Underlying: Common Stock · 2,534 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 2,534 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Apr 15, 2022 00:44 UTC Amendment | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 1,569 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014838 · doc4a.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,524 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 20:37 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,755 | $0.00 Strike: $70.64 | $0.00 |
DisclosureSEC source: 0001209191-21-026445 · doc4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,755 Underlying: Common Stock · 7,755 shares Expires 2031-04-08 F2 · derivative.exercise_date: This option was granted on April 9, 2021 with respect to 7,755 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3% vesting on April 9, 2022 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 20:37 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026445 · doc4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,955 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-21-017948 · doc4.xml · derivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in three equal annual installments on the anniversary of the grant date, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:00 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 303 | $130.51 Strike: $130.51 | $39,544.53 |
DisclosureSEC source: 0001127602-20-032588 · form4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303 Underlying: Common Stock · 303 shares Expires 2030-12-27 F3 · derivative.exercise_date: The option granted at the exercise price of $130.51 was fully vested on the date of grant. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:00 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-032588 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:40 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,444 | $133.20 Strike: $133.20 | $192,340.80 |
DisclosureSEC source: 0001127602-19-027997 · form4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444 Underlying: Common Stock · 1,444 shares Expires 2029-09-02 F3 · derivative.exercise_date: The option granted at the exercise price of $133.20 was fully vested on the date of grant. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:40 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 732 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-027997 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock Units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 16:17 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,684 | $109.97 Strike: $109.97 | $185,189.48 |
DisclosureSEC source: 0001127602-19-015919 · form4.xml · derivative · entry 2 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 Underlying: Common Stock · 1,684 shares Expires 2029-04-16 F3 · derivative.exercise_date: One third of the option granted at the exercise price of $109.97 will vest on the first anniversary of the grant date and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 16:17 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-015919 · form4.xml · nonDerivative · entry 1 Keresty Georgia · CIK 0001773532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. One third of the Restricted Stock Units will vest on the first anniversary of the grant date, and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.